WHO Prequalifies First Malaria Treatment for Newborns and Infants

The World Health Organization (WHO) has announced a significant breakthrough in global health, prequalifying the first-ever malaria treatment specifically developed for newborns and young infants. This groundbreaking medicine, known as Coartem® Baby (artemether-lumefantrine), is designed for patients weighing between two and five kilograms, an age group previously lacking tailored antimalarial formulations. This crucial prequalification was officially announced on April 24, 2026, just ahead of World Malaria Day, underscoring its urgency and importance in the global fight against malaria. The move is set to close a long-standing treatment gap, which has historically forced healthcare providers to treat infants with malaria using formulations intended for older children. Such practices often led to increased risks of incorrect dosing, potential side effects, and toxicity due to the lack of age-appropriate medication. The WHO's prequalification signifies that Coartem® Baby meets stringent international standards for quality, safety, and efficacy. This endorsement is vital as it enables public sector procurement of the medicine, making it accessible to countries and humanitarian organizations working in malaria-endemic areas. Experts anticipate that this will be particularly impactful in regions like Africa, where an estimated 30 million babies are born each year in malaria-endemic zones and desperately need effective, safe treatments. The development of Coartem® Baby is the result of a long-standing collaboration between Medicines for Malaria Venture (MMV) and Novartis, the pharmaceutical company manufacturing the treatment. Dr. Daniel Ngamije Madandi, Director of Malaria and Neglected Tropical Diseases at the WHO, highlighted that this new formulation of artemether-lumefantrine represents a significant innovation, addressing the absence of antimalarial medicines specifically developed for uncomplicated malaria in very young children. Malaria continues to be a devastating disease, particularly affecting vulnerable populations, including young children, who bear a disproportionate burden of cases and deaths. Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, emphasized the evolving narrative in the fight against malaria. He noted that new vaccines, diagnostic tests, advanced mosquito nets, and now, effective medicines tailored for the youngest patients, are collectively turning the tide against this ancient disease. He articulated a vision where ending malaria in our lifetime is a tangible possibility, provided there is sustained political and financial commitment. According to the World Malaria Report 2025, while substantial progress has been made since 2000, with an estimated 2.3 billion malaria infections prevented and 14 million lives saved, the global fight against malaria is facing challenges. The report indicated an estimated 282 million cases and 610,000 deaths in 2024, an increase from 2023 figures. Gains are at risk due to various factors, including drug resistance, insecticide resistance, diagnostic failures, and reductions in international development assistance. The prequalification of Coartem® Baby offers a renewed sense of hope, especially for the most vulnerable among those affected. The WHO prequalification process itself is a rigorous assessment that evaluates the quality, safety, and efficacy of health products. It involves thorough scientific reviews and inspections of manufacturing sites to ensure compliance with global standards. Products that successfully navigate this process are listed as prequalified and become eligible for procurement by UN agencies, governments, and other partners, thereby facilitating access to quality-assured medicines in low- and middle-income countries. For India, a country with a significant malaria burden, this development is particularly relevant. While Plasmodium vivax (P. vivax) is a predominant species in many parts of India, requiring treatments like tafenoquine (prequalified for children aged 2 and older and weighing at least 10 kg for P. vivax relapse prevention), the prequalification of artemether-lumefantrine for infants addresses the critical need for immediate treatment of acute malaria caused by various species, including the more deadly Plasmodium falciparum, which can severely affect newborns and infants. This new treatment offers a crucial tool to protect India's youngest citizens from the devastating impact of malaria, contributing to national and global elimination efforts.

Frequently Asked Questions

Read Full Story on Quick Digest